Business Description
Biotage AB
ISIN : SE0000454746
Share Class Description:
STU:PQX1: Ordinary SharesCompare
Compare
Traded in other countries / regions
BIOT.Sweden0GRP.UKBITGF.USAPQX1.Germany IPO Date
2007-11-27Description
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.25 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.47 | |||||
Interest Coverage | 5.69 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 10.18 | |||||
Beneish M-Score | -2.55 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.5 | |||||
3-Year EBITDA Growth Rate | 11 | |||||
3-Year EPS without NRI Growth Rate | 10.4 | |||||
3-Year FCF Growth Rate | -7.9 | |||||
3-Year Book Growth Rate | 44.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 28.38 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.56 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.73 | |||||
9-Day RSI | 38.62 | |||||
14-Day RSI | 45.46 | |||||
6-1 Month Momentum % | 8.48 | |||||
12-1 Month Momentum % | 66.85 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.88 | |||||
Quick Ratio | 1.14 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 216.83 | |||||
Days Sales Outstanding | 53.17 | |||||
Days Payable | 50.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.84 | |||||
Dividend Payout Ratio | 0.5 | |||||
Forward Dividend Yield % | 0.84 | |||||
5-Year Yield-on-Cost % | 0.84 | |||||
3-Year Average Share Buyback Ratio | -7.1 | |||||
Shareholder Yield % | 0.4 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 62.72 | |||||
Operating Margin % | 16.19 | |||||
Net Margin % | 12.04 | |||||
FCF Margin % | 12.54 | |||||
ROE % | 6.66 | |||||
ROA % | 5.02 | |||||
ROIC % | 6.14 | |||||
3-Year ROIIC % | 2.95 | |||||
ROC (Joel Greenblatt) % | 88.74 | |||||
ROCE % | 8.22 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 60.73 | |||||
Forward PE Ratio | 60.61 | |||||
PE Ratio without NRI | 60.73 | |||||
Shiller PE Ratio | 66.23 | |||||
Price-to-Owner-Earnings | 44.06 | |||||
PEG Ratio | 4.34 | |||||
PS Ratio | 7.57 | |||||
PB Ratio | 4.14 | |||||
Price-to-Tangible-Book | 29.6 | |||||
Price-to-Free-Cash-Flow | 60.17 | |||||
Price-to-Operating-Cash-Flow | 39.36 | |||||
EV-to-EBIT | 42.78 | |||||
EV-to-EBITDA | 28.12 | |||||
EV-to-Revenue | 7.27 | |||||
EV-to-FCF | 60.24 | |||||
Price-to-Projected-FCF | 2.48 | |||||
Price-to-DCF (Earnings Based) | 1.66 | |||||
Price-to-DCF (FCF Based) | 1.5 | |||||
Price-to-Median-PS-Value | 1.04 | |||||
Price-to-Peter-Lynch-Fair-Value | 5.3 | |||||
Price-to-Graham-Number | 8.66 | |||||
Price-to-Net-Current-Asset-Value | 101.75 | |||||
Earnings Yield (Greenblatt) % | 2.35 | |||||
FCF Yield % | 1.73 | |||||
Forward Rate of Return (Yacktman) % | 12.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biotage AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 182.498 | ||
EPS (TTM) (€) | 0.286 | ||
Beta | 1.8 | ||
Volatility % | 36.02 | ||
14-Day RSI | 45.46 | ||
14-Day ATR (€) | 0.38826 | ||
20-Day SMA (€) | 16.7675 | ||
12-1 Month Momentum % | 66.85 | ||
52-Week Range (€) | 7.285 - 17.38 | ||
Shares Outstanding (Mil) | 80.05 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Biotage AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Biotage AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Biotage AB Frequently Asked Questions
What is Biotage AB(STU:PQX1)'s stock price today?
The current price of STU:PQX1 is €16.28. The 52 week high of STU:PQX1 is €17.38 and 52 week low is €7.29.
When is next earnings date of Biotage AB(STU:PQX1)?
The next earnings date of Biotage AB(STU:PQX1) is 2024-10-23.
Does Biotage AB(STU:PQX1) pay dividends? If so, how much?
The Dividend Yield %  of Biotage AB(STU:PQX1) is 0.84% (As of Today), Highest Dividend Payout Ratio of Biotage AB(STU:PQX1) was 0.75. The lowest was 0.42. And the median was 0.54. The  Forward Dividend Yield % of Biotage AB(STU:PQX1) is 0.84%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |